Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, China.
Department of Expanded Program on Immunization, Lu'an Municipal Center for Disease Control and Prevention, Lu'an, China.
Front Public Health. 2022 Aug 1;10:943876. doi: 10.3389/fpubh.2022.943876. eCollection 2022.
There are few studies reported on the acceptance of heterologous booster vaccination for the COVID-19 vaccine among healthcare workers (HCWs) and the general population. We aimed to address that gap and explore determinant factors of acceptance of the heterologous booster vaccination.
We conducted a cross-sectional study to examine the prevalence and determinant factors of the acceptance of heterologous booster vaccination for the COVID-19 vaccine among HCWs and the targeted population.
A total of 364 HCWs and 1,898 targeted populations were investigated in our study. 76.4% HCWs would recommend heterologous booster vaccination to their patients and 59.8% targeted population endorsed a clear willingness to receive this strategy. Compared with the adenoviral vector vaccine (AD5-nCOV), recombinant protein vaccine (ZF2001) was more preferred by HCWs (79.1%) and the targeted population (72.0%) as a heterologous booster vaccine. HCWs who did not work in the vaccination clinics were more likely to recommend heterologous booster vaccination (OR = 3.3, CI: 1.5-7.3). The targeted population aged 18-59 years (OR = 1.5, 95% CI:1.1-2.3), had a positive attitude toward COVID-19 vaccination (OR = 3.8, 95% CI: 1.7-8.6), had confidence in the safety of COVID-19 vaccines (OR = 6.6, 95% CI: 4.2-10.2), followed the recommendation of HCWs (OR = 33.6, 95% CI: 22.0-51.2), took initiative in collecting booster shots information (OR = 2.1, 95% CI: 1.5-3.0), and were familiar with the heterologous strategy (OR = 1.9, 95% CI: 1.1-3.1) were more likely to choose heterologous booster vaccination. The history of side effects of inactivated COVID-19 vaccine was a negative factor in choosing heterologous booster vaccination (OR = 0.4, 95% CI: 0.4-1.0).
The heterologous booster vaccination strategy on the COVID-19 vaccine could be widely accepted among HCWs, whereas its acceptance among targeted population was only moderate. Public authorities should make efforts to communicate the public about the effectiveness and safety of the heterologous booster vaccination which could help increase their willingness to get vaccinated.
目前关于医护人员（HCWs）和普通人群对 COVID-19 疫苗异源加强针接种的接受程度，仅有少数研究报道。我们旨在填补这一空白，并探讨接受异源加强针接种的决定因素。
我们进行了一项横断面研究，以调查 HCWs 和目标人群对 COVID-19 疫苗异源加强针接种的接受率和决定因素。
本研究共调查了 364 名 HCWs 和 1898 名目标人群。76.4%的 HCWs 会向患者推荐异源加强针接种，59.8%的目标人群明确表示愿意接受这种策略。与腺病毒载体疫苗（AD5-nCOV）相比，HCWs（79.1%）和目标人群（72.0%）更倾向于将重组蛋白疫苗（ZF2001）作为异源加强针疫苗。不在疫苗接种点工作的 HCWs 更有可能推荐异源加强针接种（OR=3.3，95%CI：1.5-7.3）。18-59 岁的目标人群（OR=1.5，95%CI：1.1-2.3）、对 COVID-19 疫苗接种持积极态度（OR=3.8，95%CI：1.7-8.6）、对 COVID-19 疫苗安全性有信心（OR=6.6，95%CI：4.2-10.2）、听从 HCWs 的建议（OR=33.6，95%CI：22.0-51.2）、主动收集加强针信息（OR=2.1，95%CI：1.5-3.0）、熟悉异源策略（OR=1.9，95%CI：1.1-3.1）的人群更有可能选择异源加强针接种。接种灭活 COVID-19 疫苗后出现副作用的史（OR=0.4，95%CI：0.4-1.0）是选择异源加强针接种的负面因素。
COVID-19 疫苗的异源加强针策略在 HCWs 中得到广泛认可，而在目标人群中的接受程度仅为中等。公共卫生当局应努力向公众宣传异源加强针接种的有效性和安全性，这有助于提高他们的接种意愿。
